Radiopharm Theranostics (ASX:RAD) Reports Successful Detection of Brain Metastases with RAD 101
Clinical Trial Results
Radiopharm Theranostics reported that RAD 101 (18F-Pivalate) successfully detected brain metastases in a study involving 22 patients. The novel PET-mpMRI imaging methodology identified all brain metastases with a high tumour-to-background ratio, regardless of prior radiation treatment or tumour origin.
Ongoing Research
The company is currently recruiting for a Phase 2b imaging study in the United States to evaluate the diagnostic performance of RAD 101 in individuals with suspected recurrent brain metastases from various solid tumours.
Executive Comments
CEO Riccardo Canevari stated, “Contrast Enhanced MRI is the current standard of care but provides limited sensitivity for distinguishing disease progression from radiotherapy versus treatment effects. This is the first clinical study with 18F-RAD101 PET-mpMRI that demonstrates potentially more sensitive detection of brain metastases compared to current standard of care, offering a strong potential to improve diagnostic accuracy of suspected recurrent brain metastases.”
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.